TEST:

Cologuard®

FIT and mt-sDNA testing demonstrate low NPV and sensitivity in the high-risk CF population; these tests cannot be recommended as alternatives to colonoscopy for CRC screening for PwCF.

Updated guidelines for standardized implementation are also crucial. This review underscores the pivotal role of methylation biomarkers to revolutionize screening of CRC, while stressing the need for interdisciplinary collaboration, and outlines a strategy to address current limitations, ultimately aiming to reduce the global impact of CRC.

P=N/A, N=340, Active, not recruiting, University of California, San Diego | Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Jul 2026

In addition, 243 (13%) had prior screening that was not mapped appropriately within the EMR. The group most frequently lacking up-to-date screening was females aged 65-75 years, while the lowest percentage occurred among newly eligible patients aged 45-55 years.  Conclusion Direct patient outreach significantly improved screening uptake among eligible patients, demonstrating the effectiveness of proactive communication in a community health setting. However, barriers such as incomplete EMR documentation, patient engagement challenges, and insurance limitations persist. Enhanced outreach efforts, improved record integration, and targeted education strategies are needed to strengthen colorectal cancer screening adherence in underserved populations.

The 3-week intervention was associated with improved screening uptake, whereas the 6-week theory-informed intervention did not demonstrate a significant advantage over the control group, potentially reflecting a ceiling effect or message fatigue associated with more frequent messaging. Additionally, the study highlights unique screening patterns that contradict previous literature, underscoring the importance of a tailored approach for vulnerable communities.

P=N/A, N=12, Completed, University of California, San Diego | Active, not recruiting --> Completed | N=100 --> 12

P=N/A, N=140, Completed, UConn Health | Recruiting --> Completed | N=200 --> 140 | Trial completion date: Dec 2026 --> Jan 2026

Scenario modeling using BLUE-C prevalence estimates suggests that improving APL sensitivity from approximately 43% to 55-65% at ~94% specificity could translate to detecting roughly 13-23 additional advanced precancerous lesions per 1000 individuals screened, highlighting the potential prevention impact of a multi-omic approach. This framework aims to guide developers and clinical investigators toward next-generation stool tests capable of materially improving precursor-lesion detection while maintaining clinically acceptable specificity.

The patient had no adverse events, demonstrating the technical success of EMD in achieving en bloc R0 resection. EMD achieved en bloc R0 resection, highlighting its efficacy as a minimally invasive, organ-sparing approach for precise staging of rectal cancer.

P=N/A, N=205, Completed, Dartmouth-Hitchcock Medical Center | N=382 --> 205

Abnormal findings occurred in 57.9% of colonoscopies, 18.7% of Cologuard tests, 33.3% of mammograms, and 0% of Pap smears. This student-led outreach to patients overdue for cancer screenings facilitated referrals for colorectal, breast, and cervical cancer, supported early detection of abnormalities, and provided students with hands-on experience in preventive medicine, fostering development as community-focused physicians.